You've probably seen the headline. Something like: weight-loss jabs linked to 68% higher risk of hair loss. Scary number, right?

It's based on a real study, a large one, published in The BMJ in July 2026 by researchers at the University of Pennsylvania. But like most headline health stats, the number on its own tells you almost nothing. Let's actually look at what the study found.

What the study actually did

The researchers looked at adults with type 2 diabetes who were taking GLP-1 medications (the drug class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)). They compared them with people taking two other common diabetes medications, SGLT-2 inhibitors and DPP-4 inhibitors.

Depending on which medication they compared against, people on GLP-1s had a 37% to 68% higher relative risk of developing alopecia (hair loss).

That's where most headlines stopped. Here's what they left out.

The bit the headlines skip

A 37-68% increase sounds dramatic, but increase relative to what? In absolute terms, the actual rate was around 7 cases per 1,000 people, followed over a year. So we're talking about a small number of people affected. The relative risk jump looks much scarier than the real-world chance of it happening to you.

The type of hair loss involved was also non-scarring alopecia - meaning the hair follicles themselves aren't permanently damaged. In most cases, hair grows back.

Is it actually the drug?

This is the question nobody has a firm answer to yet. We've known for decades that rapid weight loss itself can trigger temporary hair shedding, whether that's from dieting, bariatric surgery, or illness. So this isn't something unique to GLP-1 medications.

Researchers still don't know exactly what's driving it:

• Is it the medication itself?
• Is it the speed of the weight loss?
• Is it simply eating a lot less?
• Could nutritional deficiencies, low iron or zinc for example, be contributing?
• Or is it some combination of all of the above?

It's also worth remembering this study looked specifically at people taking these medications for type 2 diabetes, not for weight management. So we can't automatically assume the findings translate exactly to everyone using GLP-1s for weight loss. The populations aren't the same.

What to actually do about it

So if you're on one of these medications and you've noticed more hair shedding than usual, please don't stop your treatment without speaking to your healthcare provider first. Make sure you're getting enough protein, and if it seems appropriate, it's worth asking about checking for nutritional deficiencies, particularly iron.

The study itself is solid, and it's genuinely useful information to have. But "68% increased risk" without the actual numbers behind it is exactly the kind of headline that's designed to make you panic first and understand later.

Reference: Tang et al., "Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation," The BMJ, July 2026.